ARTICLE | Company News
Draxis subsidiary gets Canadian approval
May 11, 2000 7:00 AM UTC
Draximage, the radiopharmaceutical subsidiary of Draxis (DRAX; TSE:DAX), received Canadian marketing approval for its BrachySeed I-125 to treat prostate cancer. The company expects to launch BrachySee...